Key result
Low-volume, single-shot crystalloid cardioplegia (Cardioplexol) during isolated aortic valve replacement was safe, with a 30-day mortality of 3%.
Why the study?
Does low-volume, single-shot crystalloid cardioplegia provide safe outcomes in patients undergoing isolated aortic valve replacement?
Observational (n=61)
Does low-volume, single-shot crystalloid cardioplegia provide safe outcomes in patients undergoing isolated aortic valve replacement?
Low-volume, single-shot crystalloid cardioplegia simplifies the procedure and appears safe for patients undergoing isolated aortic valve replacement.
Answers are grounded in this paper and cite their sources.
Supports isolated AVR use; hypothesis-generating and should not change practice absent RCTs.
We report our experience with a low-volume (100 mL), single-shot crystalloid cardioplegia (Cardioplexol) in 61 consecutive patients undergoing isolated aortic valve replacement (AVR). Cardioplexol resulted in immediate cardiac arrest. Intraoperative courses were uneventful. Postoperative markers of myocardial damage, Troponin T and CK-MB levels, were low but steadily increased with longer cross-clamp time. Thirty-day mortality was 3% and all noncardiac. Cardioplexol not only simplifies and speeds up the procedure but also seems to be safe for patients undergoing AVR.
No takes yet. Share an insight, caveat, or question.
Matt et al. (2011) conducted an observational in Isolated aortic valve replacement (n=61). Cardioplexol (low-volume, single-shot crystalloid cardioplegia) was evaluated on Thirty-day mortality. Low-volume, single-shot crystalloid cardioplegia (Cardioplexol) during isolated aortic valve replacement was safe, with a 30-day mortality of 3%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: